Glatiramer acetate liposomal - Pharmsynthez/Xenetic Biosciences

Drug Profile

Glatiramer acetate liposomal - Pharmsynthez/Xenetic Biosciences

Alternative Names: Liposomal multiple sclerosis vaccine - Pharmsynthez; MyeloXen

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmsynthez
  • Developer Pharmsynthez; Xenetic Biosciences
  • Class Peptides; Polymers
  • Mechanism of Action Immunomodulators; MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 12 Feb 2016 Discontinued - Preclinical for Multiple sclerosis in Israel (SC)
  • 21 Nov 2014 Pharmsynthez completes dosing in a phase II trial in Multiple sclerosis (Second-line therapy or greater) in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top